Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity
Serum sIL-2R in idiopathic inflammatory myopathies and controls: (a) serum sIL-2R in DM, IMNM, SLE, RA, and HCs; (b) serum sIL-2R in different myositis-specific antibody subgroups compared with HCs; (c) serum sIL-2R in treatment-naïve and previously treated DM patients; (d) serum sIL-2R in active and stable DM patients. DM: dermatomyositis; IMNM: immune-mediated necrotizing myopathy; HC: healthy control; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis. Horizontal bars represent the mean value. ,, and ; NS: not significant.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.